European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“New policy review in The Lancet Group Oncology.
A collaborative effort by Ian Tannock, Madeline Pe, the European Organisation for Research and Treatment of Cancer (EORTC), and Common Sense Oncology (CSO) stresses the critical importance of patient health-related quality of life (HRQoL) data in advanced cancer trials.
Key insights:
- HRQoL should be at least a key secondary outcome, alongside traditional clinical endpoints like overall survival
- Standardised responder criteria make HRQoL data more meaningful for patients & clinicians
- Patients must be actively involved in trial design
- Clear HRQoL reporting enables better clinical decision-making
“Our goal is to ensure the benefits of cancer treatments are fully understood, not only in terms of survival, but also how they impact patients’ daily lives.” – Prof. Ian F. Tannock, co-lead author of the paper.
Read more and access the full publication.”
More posts featuring European Organisation for Research and Treatment of Cancer.